Advances in Cardiac Tissue Engineering

A special issue of Bioengineering (ISSN 2306-5354). This special issue belongs to the section "Regenerative Engineering".

Deadline for manuscript submissions: closed (31 July 2022) | Viewed by 6424

Special Issue Editors


E-Mail Website
Guest Editor
Textile Engineering, Chemistry and Science Department, Wilson College of Textiles, NC State University, Raleigh, NC 27695, USA
Interests: stem cell niche, tissue engineering, electrospinning, cell-material interactions

E-Mail Website
Guest Editor

E-Mail Website
Guest Editor
Department of Physiology and Pathophysiology, School of Basic Medical Sciences, Fudan University, Shanghai 200032, China
Interests: engineered heart tissue; myocardial infarction; cardiac patch; injectable biomaterials; pluripotent stem cells; heart failure; cardiomyopathy

Special Issue Information

Dear Colleagues,

Recent advances have led to exciting developments in cardiac tissue engineering, ranging from stem cell-derived constructs to new clinical treatments to 3D bioprinting vasculature. In particular, biomaterial, cellular, and hybrid composites have made strides in the field and can be used for enhanced drug screening, better disease modeling, and clinically relevant regenerative medicine. The exciting multidisciplinary field of cardiac tissue engineering includes biology, electrophysiology, biomaterials and materials science, and bioengineering. Efforts have been made to recapitulate the complex cardiac microenvironment using functional biomaterials. The unique microenvironment includes complex and combinatorial physiological, mechanical and biochemical cues. The physical properties and architecture of cardiac tissue influence both function and differentiation. Functional engineered cardiac tissue has the potential to improve our understanding and approach to cardiology and cardiac disorders.

The aim of this Special Issue is to present the state-of-the-art progress on such advances in cardiac tissue engineering and their scientific and clinical applications. We welcome original research articles, comprehensive reviews, methods, mini-reviews, and perspectives including (but not limited to) the following topics: 3D bioprinting cardiac tissue, tissue biomanufacturing to create functional cardiac tissue, advanced biomaterials systems to model cardiac tissues, and stem cell-based approaches.

Dr. Jessica Gluck
Prof. Dr. George Truskey
Prof. Dr. Ning Sun
Guest Editors

Manuscript Submission Information

Manuscripts should be submitted online at www.mdpi.com by registering and logging in to this website. Once you are registered, click here to go to the submission form. Manuscripts can be submitted until the deadline. All submissions that pass pre-check are peer-reviewed. Accepted papers will be published continuously in the journal (as soon as accepted) and will be listed together on the special issue website. Research articles, review articles as well as short communications are invited. For planned papers, a title and short abstract (about 100 words) can be sent to the Editorial Office for announcement on this website.

Submitted manuscripts should not have been published previously, nor be under consideration for publication elsewhere (except conference proceedings papers). All manuscripts are thoroughly refereed through a single-blind peer-review process. A guide for authors and other relevant information for submission of manuscripts is available on the Instructions for Authors page. Bioengineering is an international peer-reviewed open access monthly journal published by MDPI.

Please visit the Instructions for Authors page before submitting a manuscript. The Article Processing Charge (APC) for publication in this open access journal is 2700 CHF (Swiss Francs). Submitted papers should be well formatted and use good English. Authors may use MDPI's English editing service prior to publication or during author revisions.

Keywords

  • cardiac tissue engineering
  • cardiac regeneration
  • 3D bioprinting
  • cardiovascular disease modeling
  • cardiac drug screening
  • cardiac patch constructs
  • in vitro cardiac culture systems
  • cardiac cell therapies
  • electrophysiology

Published Papers (2 papers)

Order results
Result details
Select all
Export citation of selected articles as:

Review

14 pages, 1164 KiB  
Review
Advances in Cardiac Tissue Engineering
by Takahiro Kitsuka, Fuga Takahashi, James Reinhardt, Tatsuya Watanabe, Anudari Ulziibayar, Asigul Yimit, John Kelly and Toshiharu Shinoka
Bioengineering 2022, 9(11), 696; https://0-doi-org.brum.beds.ac.uk/10.3390/bioengineering9110696 - 16 Nov 2022
Cited by 3 | Viewed by 1915
Abstract
Tissue engineering has paved the way for the development of artificial human cardiac muscle patches (hCMPs) and cardiac tissue analogs, especially for treating Myocardial infarction (MI), often by increasing its regenerative abilities. Low engraftment rates, insufficient clinical application scalability, and the creation of [...] Read more.
Tissue engineering has paved the way for the development of artificial human cardiac muscle patches (hCMPs) and cardiac tissue analogs, especially for treating Myocardial infarction (MI), often by increasing its regenerative abilities. Low engraftment rates, insufficient clinical application scalability, and the creation of a functional vascular system remain obstacles to hCMP implementation in clinical settings. This paper will address some of these challenges, present a broad variety of heart cell types and sources that can be applied to hCMP biomanufacturing, and describe some new innovative methods for engineering such treatments. It is also important to note the injection/transplantation of cells in cardiac tissue engineering. Full article
(This article belongs to the Special Issue Advances in Cardiac Tissue Engineering)
Show Figures

Figure 1

16 pages, 1206 KiB  
Review
Bioengineering Strategies to Create 3D Cardiac Constructs from Human Induced Pluripotent Stem Cells
by Fahimeh Varzideh, Pasquale Mone and Gaetano Santulli
Bioengineering 2022, 9(4), 168; https://0-doi-org.brum.beds.ac.uk/10.3390/bioengineering9040168 - 10 Apr 2022
Cited by 11 | Viewed by 3916
Abstract
Human induced pluripotent stem cells (hiPSCs) can be used to generate various cell types in the human body. Hence, hiPSC-derived cardiomyocytes (hiPSC-CMs) represent a significant cell source for disease modeling, drug testing, and regenerative medicine. The immaturity of hiPSC-CMs in two-dimensional (2D) culture [...] Read more.
Human induced pluripotent stem cells (hiPSCs) can be used to generate various cell types in the human body. Hence, hiPSC-derived cardiomyocytes (hiPSC-CMs) represent a significant cell source for disease modeling, drug testing, and regenerative medicine. The immaturity of hiPSC-CMs in two-dimensional (2D) culture limit their applications. Cardiac tissue engineering provides a new promise for both basic and clinical research. Advanced bioengineered cardiac in vitro models can create contractile structures that serve as exquisite in vitro heart microtissues for drug testing and disease modeling, thereby promoting the identification of better treatments for cardiovascular disorders. In this review, we will introduce recent advances of bioengineering technologies to produce in vitro cardiac tissues derived from hiPSCs. Full article
(This article belongs to the Special Issue Advances in Cardiac Tissue Engineering)
Show Figures

Figure 1

Back to TopTop